Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 54 min ago
Peer-reviewedCC BY-NC-NDInternational journal of cardiology. Congenital heart disease

Anticoagulation management and valve-related outcomes after mechanical valve implantation in patients with Fontan palliation

  • Audrey C. Bankes1
  • David S. Majdalany2
  • Maan Jokhadar2
  • Joseph A. Dearani3
  • Alexander C. Egbe2
  1. 1Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, 55905, USA
  2. 2Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 55905, USA
  3. 3Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 55905, USA
Read full textPDFDOICite

Abstract

Background

Valvular dysfunction is a major contributor to morbidity in adults with Fontan palliation. Mechanical valve replacement offers superior durability compared with bioprostheses but requires lifelong anticoagulation, raising concern in the prothrombotic and low-flow Fontan circulation. Data on long-term outcomes after mechanical valve implantation in this population remains limited.Objectives

To evaluate long-term bleeding, thromboembolic, valve-related, and cardiovascular outcomes after mechanical valve replacement in adults with Fontan palliation.Methods

We retrospectively studied 26 adults with Fontan circulation who underwent mechanical aortic or atrioventricular valve replacement between 2003 and 2024. Outcomes included (1) major bleeding/thromboembolic complications, (2) valve-related complications, and (3) composite cardiovascular events (valve-related complications, death, or transplant). Events were analyzed as time-to-event endpoints. Anticoagulation control was assessed by time in therapeutic range (TTR).Results

Median age at valve implantation was 21 (15-28) years. Fifteen prostheses were implanted in the atrioventricular position and 11 in the aortic position. Median follow-up was 14.3 years (364 patient-years). TTR was 71% for atrioventricular and 79% for aortic prostheses. Four patients experienced major bleeding/thromboembolic events. Ten- and 20-year cumulative incidences of major bleeding/thromboembolism were 9% and 22%, respectively. Valve-related complication rates were 13% and 28% at 10 and 20 years. Composite cardiovascular event rates were 31% and 60% at 10 and 20 years, driven primarily by progressive Fontan failure rather than prosthetic dysfunction.Conclusions

Mechanical valve replacement in selected Fontan patients provides durable valve performance with acceptable long-term complication rates. Outcomes appear largely determined by the natural history of Fontan physiology rather than prosthesis-related failure.

Related

  1. Outcomes after conversion from mechanical to bioprosthetic valves for anticoagulation-related complications.
    Vincy Tam, Hartzell V Schaff, Kevin L Greason +5
    JTCVS openPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMCPMC
  2. Non-Cardiac Surgery After Left Ventricular Assist Device Implantation: Perioperative Management and Outcomes from a Single Center
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. Cardiovascular magnetic resonance–derived hemodynamics predict adverse outcomes after Fontan palliation
    Carson Platnick, Benjamin Frank, Jennifer Romanowicz +9
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
  4. Mechanical Complications After Acute Myocardial Infarction: Contemporary Management, Treatment Selection, and Outcomes in a 10-Year Regional Referral Network
    Alberto Alén, Andrés Álvarez-Gato, Manuel Sánchez +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  5. Investigation of surface anticoagulation in electrically active mechanical mitral valve in swine model
    Lokeswara Rao Sajja, Thomas Mathew, Aditya Koppula
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicineCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{bankes2026anticoagulation,
  title = {{Anticoagulation management and valve-related outcomes after mechanical valve implantation in patients with Fontan palliation}},
  author = {Audrey C. Bankes and David S. Majdalany and Maan Jokhadar and Joseph A. Dearani and Alexander C. Egbe},
  journal = {International journal of cardiology. Congenital heart disease},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ijcchd.2026.100719},
  url = {https://europepmc.org/article/PMC/PMC13717882},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Anticoagulation management and valve-related outcomes after mechanical valve implantation in patients with Fontan palliation
AU  - Audrey C. Bankes
AU  - David S. Majdalany
AU  - Maan Jokhadar
AU  - Joseph A. Dearani
AU  - Alexander C. Egbe
PY  - 2026
DA  - 2026/10/04
JO  - International journal of cardiology. Congenital heart disease
DO  - 10.1016/j.ijcchd.2026.100719
UR  - https://europepmc.org/article/PMC/PMC13717882
AB  - Background  Valvular dysfunction is a major contributor to morbidity in adults with Fontan palliation. Mechanical valve replacement offers superior durability compared with bioprostheses but requires lifelong anticoagulation, raising concern in the prothrombotic and low-flow Fontan circulation. Data on long-term outcomes after mechanical valve implantation in this population remains limited.Objectives  To evaluate long-term bleeding, thromboembolic, valve-related, and cardiovascular outcomes after mechanical valve replacement in adults with Fontan palliation.Methods  We retrospectively studied 26 adults with Fontan circulation who underwent mechanical aortic or atrioventricular valve replacement between 2003 and 2024. Outcomes included (1) major bleeding/thromboembolic complications, (2) valve-related complications, and (3) composite cardiovascular events (valve-related complications, death, or transplant). Events were analyzed as time-to-event endpoints. Anticoagulation control was assessed by time in therapeutic range (TTR).Results  Median age at valve implantation was 21 (15-28) years. Fifteen prostheses were implanted in the atrioventricular position and 11 in the aortic position. Median follow-up was 14.3 years (364 patient-years). TTR was 71% for atrioventricular and 79% for aortic prostheses. Four patients experienced major bleeding/thromboembolic events. Ten- and 20-year cumulative incidences of major bleeding/thromboembolism were 9% and 22%, respectively. Valve-related complication rates were 13% and 28% at 10 and 20 years. Composite cardiovascular event rates were 31% and 60% at 10 and 20 years, driven primarily by progressive Fontan failure rather than prosthetic dysfunction.Conclusions  Mechanical valve replacement in selected Fontan patients provides durable valve performance with acceptable long-term complication rates. Outcomes appear largely determined by the natural history of Fontan physiology rather than prosthesis-related failure.
SN  - 2666-6685
ER  -